September 29, 2026

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: Exploring a 47.99% Potential Upside in the Dental Industry

Investors with an eye on the healthcare sector might find DENTSPLY SIRONA Inc. (XRAY) an intriguing prospect, given its prominent presence in the medical instruments and supplies industry. Despite facing..

Belite Bio, Inc (BLTE) Stock Analysis: A 37.94% Potential Upside Amidst Promising Drug Developments

Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical company headquartered in San Diego, California, is drawing significant attention from the investor community. The company, with a market capitalization of $6.68..

Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Exploring a 10.80% Potential Upside

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a leader in the healthcare sector, particularly within the specialty and generic drug manufacturing industry, has recently caught the attention of investors due to its..

Veracyte, Inc. (VCYT) Stock Analysis: A Potential 29% Upside for Investors in the Diagnostics Field

Veracyte, Inc. (VCYT), a prominent player in the healthcare sector, specifically within the diagnostics and research industry, presents a compelling investment opportunity with a potential upside of 29.15%. The company,..

Privia Health Group, Inc. (PRVA) Stock Analysis: A Strong Buy Consensus with a Potential 58% Upside

Privia Health Group, Inc. (NASDAQ: PRVA), a prominent player in the healthcare sector, is garnering significant investor attention with its potential for impressive growth. As a national physician-enablement company based..

Zai Lab Limited (ZLAB) Stock Analysis: Exploring a 29% Potential Upside Amidst Strong Buy Ratings

Investors looking for opportunities in the biotechnology sector may want to consider Zai Lab Limited (NASDAQ: ZLAB), a Chinese biopharmaceutical company with a market capitalization of $2.88 billion. Despite the..

Viking Therapeutics, Inc. (VKTX) Stock Analysis: Potential Upside of 187% Sparks Investor Interest

Viking Therapeutics, Inc. (NASDAQ: VKTX), a biopharmaceutical company at the forefront of metabolic and endocrine disorder therapies, is capturing attention with a staggering potential upside of 187.06%. The company’s market..

PROCEPT BioRobotics (PRCT) Stock Analysis: Navigating a Promising 25% Upside in the Medical Device Sector

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) stands at the intersection of healthcare innovation and investment potential. With its focus on developing transformative robotic solutions for urology, the company is making strides..

Perrigo Company plc (PRGO) Stock Analysis: Understanding the 7.68% Dividend Yield and Growth Potential

Perrigo Company plc (NYSE: PRGO) presents itself as a significant player in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. Headquartered in Dublin, Ireland, Perrigo offers..

RM heads to EDUtech Asia 2026 to expand education technology reach

RM will attend EDUtech Asia 2026 in Singapore in November, highlighting its digital assessment capabilities and its experience implementing on-screen marking for national examinations...

Record Currency Management wins $3bn FX Alpha mandate as frontier strategy expands

Record has secured a USD 3bn FX Alpha mandate and an initial USD 80m FX Frontier mandate, expanding the scale of its investment management operations across developed and frontier markets...

GSTechnologies completes $1m AI investment and cuts debt

GSTechnologies has completed a US$1m investment in Singapore-based Sodales AI for a 10% equity stake, supporting its strategy to combine AI with fintech, blockchain and digital payments. The company has..

Syncona strengthens leadership to drive portfolio value creation

Syncona Investment Management has appointed Chris Hollowood as Chief Investment Officer and Sam Roberts as Managing Director as its portfolio moves further towards clinical-stage companies. Roel Bulthuis will become an..

AstraZeneca invests $2bn in Summit to accelerate ivonescimab development

AstraZeneca will invest $2bn in Summit Therapeutics to accelerate the development of ivonescimab and expand its potential use in combination with ADCs. The companies will also collaborate on trials combining..

ZIGUP raises profit outlook to top of £170m range

ZIGUP expects adjusted profit before tax to reach the top of its £163.2m to £170.0m market expectations range, driven by strong performance in Spain and FMG. Average vehicle on hire..

KEFI reports £87m net assets as Tulu Kapi development advances

KEFI Gold and Copper increased net assets to £87m at 30 June 2026 after completing its £35.6m equity raise, while Tulu Kapi development progressed following completion of its US$400m-plus funding..

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued..

Close Brothers cuts costs by £36m as loan growth returns

Close Brothers delivered £36m of annualised cost savings in FY 2026, ahead of its £25m target, while loan book growth resumed in the second half. The group expects to exceed..

Alien Metals confirms 1,800m Elizabeth Hill silver drilling programme

Alien Metals’ joint venture partner West Coast Silver will begin an 18-hole, approximately 1,800m diamond drilling programme at Elizabeth Hill in Western Australia in October. The programme will target resource..

Genflow completes SLAB trial as human and animal health programmes advance

Genflow Biosciences completed its SLAB canine healthspan and sarcopenia trial in H1 2026, with the company reporting safety and tolerability data for GF-1004. The group also advanced its glaucoma, MASH,..
Search

Funds

September 29, 2026

RM heads to EDUtech Asia 2026 to expand education technology reach

RM will attend EDUtech Asia 2026 in Singapore in November, highlighting its digital assessment capabilities and its experience implementing on-screen marking for national examinations...

Record Currency Management wins $3bn FX Alpha mandate as frontier strategy expands

Record has secured a USD 3bn FX Alpha mandate and an initial USD 80m FX Frontier mandate, expanding the scale of its investment management operations across developed and frontier markets...

GSTechnologies completes $1m AI investment and cuts debt

GSTechnologies has completed a US$1m investment in Singapore-based Sodales AI for a 10% equity stake, supporting its strategy to combine AI with fintech, blockchain and digital payments. The company has also prepaid US$1m of its US$10m term loan, reducing the outstanding facility to US$9m...

Syncona strengthens leadership to drive portfolio value creation

Syncona Investment Management has appointed Chris Hollowood as Chief Investment Officer and Sam Roberts as Managing Director as its portfolio moves further towards clinical-stage companies. Roel Bulthuis will become an Executive Partner, continuing to support the investment team and portfolio...

AstraZeneca invests $2bn in Summit to accelerate ivonescimab development

AstraZeneca will invest $2bn in Summit Therapeutics to accelerate the development of ivonescimab and expand its potential use in combination with ADCs. The companies will also collaborate on trials combining ivonescimab with Sone-Ve across gastrointestinal cancers...

ZIGUP raises profit outlook to top of £170m range

ZIGUP expects adjusted profit before tax to reach the top of its £163.2m to £170.0m market expectations range, driven by strong performance in Spain and FMG. Average vehicle on hire is more than 5% ahead of last year, with the Spanish fleet now exceeding 80,000 vehicles...

KEFI reports £87m net assets as Tulu Kapi development advances

KEFI Gold and Copper increased net assets to £87m at 30 June 2026 after completing its £35.6m equity raise, while Tulu Kapi development progressed following completion of its US$400m-plus funding package...

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation...

Close Brothers cuts costs by £36m as loan growth returns

Close Brothers delivered £36m of annualised cost savings in FY 2026, ahead of its £25m target, while loan book growth resumed in the second half. The group expects to exceed £60m of annualised savings by FY 2027 and is targeting 5-10% annual loan book growth through the cycle...

Alien Metals confirms 1,800m Elizabeth Hill silver drilling programme

Alien Metals’ joint venture partner West Coast Silver will begin an 18-hole, approximately 1,800m diamond drilling programme at Elizabeth Hill in Western Australia in October. The programme will target resource definition, extensions and new high-grade silver zones ahead of a March 2027 mineral resource update and Scoping Study...

Genflow completes SLAB trial as human and animal health programmes advance

Genflow Biosciences completed its SLAB canine healthspan and sarcopenia trial in H1 2026, with the company reporting safety and tolerability data for GF-1004. The group also advanced its glaucoma, MASH, Mitosir and Exofastrack programmes while ending the period with £632,553 in cash...
Search

Funds

September 29, 2026

FTSE 100

Funds